{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-202313","form_type":"8-K","ticker":"ALNY","cik":"0001178670","company_name":"ALNYLAM PHARMACEUTICALS, INC.","filed_at":"2023-08-03T23:59:59+00:00","discovered_at":"2026-05-14T18:03:33.320707+00:00","generated_at":"2026-06-12T07:18:23.122627+00:00","sec_items":["2.02","5.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Alnylam Q2 net product revenues up 43% to $306M; Vaishnaw steps down as President","bullets":["Net product rev $306M (+43% YoY); GAAP net loss $276M ($2.21/share), non-GAAP net loss $202M ($1.62/share).","AMVUTTRA rev $132M, ONPATTRO $91M, GIVLAARI $58M, OXLUMO $24M; total TTR growth 72% in U.S.","Reiterated 2023 guidance: combined net product rev $1.2B-$1.285B.","U.S. Attorney's Office closed ONPATTRO marketing investigation with no action.","President Akshay Vaishnaw transitions to part-time Chief Innovation Officer, effective Oct 2, 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-202313","json":"https://secwatch.observer/filing/0001193125-23-202313.json","markdown":"https://secwatch.observer/filing/0001193125-23-202313.md","text":"https://secwatch.observer/filing/0001193125-23-202313.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1178670/000119312523202313/0001193125-23-202313-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1178670/000119312523202313/d472276d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-12T07:18:23.122627+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"9a0611bc13741bfd764685ed5a0f20a57b77dd14","claim":"ALNYLAM PHARMACEUTICALS, INC. updated its the second quarter ended June 30, 2023 guidance (reaffirmed).","evidence_excerpt":"On August 3, 2023, Alnylam Pharmaceuticals, Inc. (the “Company”) announced its financial results for the quarter ended June 30, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1178670/000119312523202313/0001193125-23-202313-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the second quarter ended June 30, 2023"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"65e1a15d21","claim":"Akshay K. Vaishnaw changed role as Chief Innovation Officer at ALNYLAM PHARMACEUTICALS, INC..","evidence_excerpt":"On July 31, 2023, the Company and Akshay K. Vaishnaw, M.D., Ph.D. entered into a letter agreement (the “Letter Agreement”), whereby Dr. Vaishnaw will leave his current position as President of the Company and transition to a part-time role as Chief Innovation Officer, effective October 2, 2023 (the “Transition Date”).","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1178670/000119312523202313/0001193125-23-202313-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"transitioned"},{"label":"Role","value":"Chief Innovation Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}